|
|
|
| Clinical effect evaluation of Thymosin combined with antituberculosis drugs in the treatment of multi-drug resistant tuberculosis |
| XU Jiang-tao1 HU Xiao-hong2 WANG Yu-min3 |
1.Shenyang Chest Hospital,Liaoning Province,Shenyang 110044,China;
2.Department of Cadre,Northern Theater Command Air Force Hospital,Liaoning Province,Shenyang 110015,China;
3.Medical Team,Security Department,the Fifth Brigade of Air Force Information,Northern Theater Command,Liaoning Province,Shenyang 110015,China |
|
|
|
|
Abstract Objective To investigate the therapeutic effect of Thymosin combined with antituberculosis drugs in the treatment of multi-drug resistant tuberculosis.Methods From December 7,2015 to January 1,2017,68 patients with multi-drug resistant tuberculosis treated in Shenyang Chest Hospital were selected as subjects.They were evenly divided into two groups according to the complete random principle,34 cases in each group.according to different treatment methods.In the control group,conventional anti-tuberculosis drug treatment was used,while on the basis of the control group,Thymosin was added in the observation group.The biochemical indicators,sputum negative conversion,cavity closure and occurrence of adverse events were observed.Results There was no statistically significant difference between the two groups of patients before and after treatment of hemoglobin,alanine transaminase and urea nitrogen levels(P＞0.05).Treatment for 3 months,treatment for half year and end of treatment,the rates of sputum negative conversion in the observation group(52.94%,64.71%,73.53%)were higher than those of the control group(29.41%,38.24%,44.12%),and the differences were statistically significant(P＜0.05).Treatment for 3 months and end of treatment,the rates of cavity closure in the observation group(29.41%,55.88%)were higher than those of the control group(5.88%,32.35%),and the differences were statistically significant(P＜0.05),while there was no statistically significant difference of the cavity closure rate between two groups of treatment for half year(P＞0.05).There was no statistically significant difference in the incidence of adverse events between the two groups (P＞0.05).Conclusion In the treatment of multi-drug resistant tuberculosis,anti-tuberculosis drugs combined with Thymosin has a great effect,which can significantly alleviate the disease condition and promote the recovery in high safety.
|
|
|
|
|
|
| [1] |
龚年金.左氧氟沙星及胸腺肽联合2HRZE/4HR方案治疗初治肺结核的临床疗效及对痰上清液细胞因子水平的影响[J].实用心脑肺血管病杂志，2016，24（7）：117-120.
|
| [2] |
韩伟，崔泰震，黄健，等.胸腺肽联合抗结核药物治疗耐多药肺结核临床疗效[J].新乡医学院学报，2015，32（12）：1106-1109.
|
| [3] |
翁加豪，杨仪，陈伟生，等.依替米星联合胸腺肽肠溶片治疗耐多药肺结核对疗效改善、肺功能及生活质量的影响[J].黑龙江医学，2016，40（12）：1134-1136.
|
| [4] |
吴小霞，辛朝雄，杨俭，等.含环丝氨酸联合胸腺肽方案治疗耐多药肺结核的临床研究[J].北方药学，2016，13（5）：106-107.
|
| [5] |
邹国强，温红光，赖映君，等.胸腺肽联合抗结核药物治疗耐多药肺结核疗效观察[J].中国实用医药，2017，12（20）：19-21.
|
| [6] |
辛朝雄，吴小霞，杨俭，等.含环丝氨酸联合胸腺肽方案治疗耐多药肺结核的效果[J].广东医学，2016，37（17）：2646-2651.
|
| [7] |
王鲲.莫西沙星联合胸腺肽治疗耐多药肺结核的临床效果观察[J].中国现代药物应用，2015，9（22）：100-101.
|
| [8] |
王真茹.探讨胸腺肽联合抗结核药治疗复治涂阳肺结核的效果[J].中国医药指南，2016，14（9）：84-85.
|
| [9] |
罗朝晖，牟建珍.胸腺肽联合抗结核药治疗复治涂阳肺结核的临床效果探讨[J].现代诊断与治疗，2016，27（24）：4728-4729.
|
| [10] |
范爱平，刘密霞.胸腺肽α1联合短程化疗治疗肺结核伴糖尿病患者的效果评价[J].临床医药文献电子杂志，2017，4（28）：5413.
|
| [11] |
陈雪霞.胸腺肽联合抗结核药治疗复治涂阳肺结核的效果研究[J].中国现代药物应用，2017，11（16）：123-124.
|
| [12] |
刘淑红.胸腺肽联合抗结核药治疗复治涂阳肺结核临床观察[J].临床医药文献电子杂志，2017，4（16）：3128.
|
| [13] |
陆小玲.胸腺肽联合抗结核药治疗复治涂阳肺结核的临床疗效[J].中国继续医学教育，2016，8（28）：164-166.
|
| [14] |
朱倬敏.左氧氟沙星联合胸腺肽治疗老年初治肺结核疗效观察[J].国际医药卫生导报，2017，23（9）：1426-1428.
|
| [15] |
余禄.胸腺肽联合抗结核药治疗肺结核30例体会[J].世界最新医学信息文摘：连续型电子期刊，2015，15（52）：57.
|
|
|
|
